Important Notices

On Jan. 10, 2025, Grifols Therapeutics LLC withdrew one lot to the consumer level for Xembify® (immune globulin subcutaneous, human-klhw) 20% 4G vial due to an increased rate of reported hypersensitivity reactions with the affected lot.

On Jan. 16, 2025, the FDA warned healthcare professionals not to use unapproved epinephrine nasal solutions from BPI Labs and Endo

On Jan. 13, 2025, Grifols Therapeutics LLC withdrew one lot to the consumer level for Xembify® (immune globulin subcutaneous, human-klhw) 20% 4G vial

Orders may arrive late due to Winter Weather.